NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900’s unique mechanism of action enables the inhibition of both the catalytic and scaffolding ...

Treatment with tarlatamab-dlle (Imdelltra) had a positive benefit-risk profile when used in previously treated patients with small cell lung cancer (SCLC), according to patient-reported outcomes (PROs ...

Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in Waldenström macroglobulinemia. The FDA granted bexobrutideg (NX-5948) orphan ...

After hours: March 17 at 4:05:11 PM EDT Loading Chart for NVCT ...